The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AstraZeneca swings to profit; Unilever volumes fall

Thu, 09th Feb 2023 07:55

(Alliance News) - Stocks in London were called to open higher on Thursday, as investors in Europe kept their cool, despite hawkish US central bankers and a weak finish on Wall Street.

Sentiment in New York was undermined by the latest comments by a Federal Reserve official, seeming to indicated high interest rates could persist for "a few years".

In comments reported by Bloomberg, Fed Vice Chair John Williams advocated for a "sufficiently restrictive stance of policy", adding that interest rates were "barely into restrictive territory".

"We're going to need to maintain that for a few years to make sure we get inflation to 2%, and then eventually over time we'll get interest rates presumably back to more normal levels," Williams said.

Fed Governor Christopher Waller added: "It might be a long fight, with interest rates higher for longer than some are currently expecting."

Meanwhile, Minneapolis Fed President Neel Kashkari warned there was "not yet much evidence, in my judgment, that the rate hikes that we've done so far are having much effect on the labour market".

"We need to bring the labour market into balance, so that tells me we need to do more."

"So, the message is clear. The Fed is not done yet. This means that the rate hikes will continue, and that will continue pressuring the US yields higher as well," said Swissquote Bank's Ipek Ozkardeskaya.

Meanwhile, Europe's largest economy saw inflation speed up slightly at the beginning of the year, according to preliminary figures released early Thursday.

Destatis said consumer prices in Germany rose 1.0% in January from the month before, reversing a 0.8% monthly decline in December. Annual inflation ticked up to 8.7% from 8.6% at the end of 2022.

On a harmonised basis - which allows for EU-wide comparison - prices rose 0.5% on a monthly basis, compared to a 1.2% fall in December. Harmonised annual inflation eased to 9.2% from 9.6% a month before, however.

In early corporate news, AstraZeneca saw double-digit annual sales growth in 2022, despite a weaker fourth quarter, while Unilever said a fall in annual sales volumes is likely to persist into the first half of 2023.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 22.7 points, 0.3%, at 7,907.87

----------

Hang Seng: up 1.5% at 21,592.60

Nikkei 225: closed down 0.1% at 27,584.35

S&P/ASX 200: closed down 0.5% at 7,490.30

----------

DJIA: closed down 207.68 points, or 0.6%, at 33,949.01

S&P 500: closed down 46.14 points, or 1.1%, at 4,117.86

Nasdaq Composite: closed down 203.27 points, or 1.7%, at 11,910.52

----------

EUR: up at USD1.0738 (USD1.0734)

GBP: up at USD1.2097 (USD1.2084)

USD: flat at JPY131.28 (JPY131.29)

GOLD: up at USD1,880.75 per ounce (USD1,878.10)

OIL (Brent): up at USD85.17 a barrel (USD84.01)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

08:30 EST US unemployment insurance weekly claims report

08:30 EST US weekly export sales

16:30 EST US Foreign Central Bank holdings

16:30 EST US federal discount window borrowings

----------

UK house prices are starting to reflect the shift in demand in the market, according to surveyors. Agreed sales, house prices and new instructions to sell homes remained on a downward trend in January, the Royal Institution of Chartered Surveyors said. Property professionals' expectations suggest this picture is likely to remain in place for a while longer as the market adjusts to higher interest rates, Rics' report added. A net balance of 47% of surveyors reported seeing a fall rather than an increase in new buyer inquiries, deteriorating from a balance of 40% who saw this the previous month.

----------

Civil servants working in the UK government's biggest department start 20 days of strikes as part of the long-running dispute over pay, jobs, pensions and conditions. Members of the Public & Commercial Services union working for the Department for Work & Pensions in a number of jobcentres and other offices will be involved in the action. The PCS said around 500 of its members in Bolton and Stockport and 170 in jobcentres in Liverpool will strike in the coming weeks.

----------

BROKER RATING CHANGES

----------

Berenberg starts Ashtead Technology with 'buy' - price target 405 pence

----------

Barclays starts Ithaca Energy with 'underweight' - price target 140 pence

----------

HSBC cuts Hiscox to 'hold' (buy) - price target 1,250 (1,150) pence

----------

COMPANIES - FTSE 100

----------

British American Tobacco said revenue rose 7.7% in 2022, reaching GBP27.66 billion from GBP25.68 billion, with GBP2.89 billion coming from New Categories, which saw 41% growth. Pretax profit edged up to GBP9.32 billion from GBP9.16 billion. Looking ahead to 2023, BAT expects global tobacco industry volume to fall by around 2%. The Dunhill cigarette maker expects 3% to 5% organic constant currency revenue growth, with strong growth expected in New Categories, which includes heated and vaping products. It expects mid-single figure constant currency adjusted earnings per share growth, which will be weighted towards the second half. CEO Jack Bowles expects the macro-economic environment to "remain challenging", but is confident of delivering "long-term sustainable value" for BAT's shareholders.

----------

AstraZeneca said total revenue in 2022 rose by 19% to USD44.35 billion from USD37.42 billion a year before, or by 24% at constant currency. Growth came from all therapy areas, as well as the addition of Alexion. Astra swung to a pretax profit of USD2.50 billion from a loss of USD265 million, while core earnings per share jumped 26% to USD6.66. The pharmaceutical maker saw a weaker fourth quarter, however, as revenue fell by 7% to USD11.21 billion and core EPS fell by 17% to USD1.38. The lower revenue in the quarter was partly due to the decline in Vaxzevria, Astra said. Revenue excluding Vaxzevria rose 17%. Looking ahead, Astra expects revenue in 2023 to grow at low-to-mid single-digit percentages at constant currency, or by low double-digit percentages excluding Covid-19 medicines. Core EPS is expected to see high single-digit to low double-digit growth.

----------

Consumer goods firm Unilever said annual turnover rose 15% year-on-year to EUR60.07 billion from EUR52.44 billion, as pretax profit rose 21% to EUR10.34 billion from EUR8.56 billion. Underlying sales growth was 9.0%, driven by price growth, given that volumes fell 2.1%. In 2023, Unilever expects to deliver strong underlying sales growth and improving volume performance. It said net material inflation in the first half is expected to be around EUR1.5 billion, but will be "significantly lower" in the second half. It expects underlying price growth to remain high and volumes to fall in the first half, but said it is "too early to say" whether volumes will see positive growth in the second half. Unilever expects 2023 underlying sales growth to be at least in the upper half of a 3% to 5% range. "Despite sharp rises in material costs, we have prioritised stepping up our brand and marketing investment," said CEO Alan Jope.

----------

COMPANIES - FTSE 250

----------

Watches of Switzerland reported double-digit growth in its financial third quarter ended January 29, as revenue rose 17% year-on-year to GBP407 million from GBP348 million. This was driven by luxury watches, "where demand continues to exceed supply". The firm remains confident of delivery long-term growth. For the whole of financial 2023, Watches expects to bring in revenue of GBP1.50 billion to GBP1.55 billion, with adjusted earnings before interest and tax to be between GBP163 million to GBP175 million. The guidance is on a pre-IFRS 16 basis, with a constant exchange rate applied to the fourth quarter. CEO Brian Duffy reports the firm's expansion into Europe is seeing "positive" early trading.

----------

OTHER COMPANIES

----------

Japan's Toyota Motor left its annual forecasts unchanged despite ongoing disruption from the global chip shortage. The world's top-selling automaker, which reshuffled its executive line-up last month, is still suffering production setbacks caused by the semiconductor shortage along with other industry players. But it said it still expects net profit of JPY2.36 trillion, about USD18 billion, in the 12 months to March 2023, down 17% on-year. Toyota logged a third-quarter net profit of JPY727.9 billion, down 8% on-year, and for April-December, net profit dropped 18% to JPY1.90 trillion. Sales revenue rose 18% to JPY27.464 trillion from JPY23.267 trillion.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.